Skip to main navigation Skip to search Skip to main content

Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid–octadecylamine conjugate

  • Jing Sun
  • , Yanzhi Song
  • , Mei Lu
  • , Xiangyun Lin
  • , Yang Liu
  • , Songlei Zhou
  • , Yuqing Su
  • , Yihui Deng*
  • *Corresponding author for this work
  • Shenyang Pharmaceutical University

Research output: Contribution to journal › Article › peer-review

Abstract

Dexamethasone palmitate has the potential to inhibit the activity of tumor-associated macrophages, which promote cancer proliferation, invasion, and metastasis; however, only very high and frequent doses are capable of inducing antitumor effects. With the aim to reduce the anticancer dose and decrease the nonspecific toxicity, we designed a liposomal system to co-deliver dexamethasone palmitate and doxorubicin. Furthermore, a ligand conjugate sialic acid–octadecylamine, with enhanced affinity towards the membrane receptors over-expressed in tumors, was anchored on the surface of the liposomes to increase drug distribution to the tumor tissue. Co-loaded liposomes were developed using lipid film hydration method to load dexamethasone palmitate and remote loading technology to load doxorubicin. The co-loaded liposomes modified with sialic acid–octadecylamine represented comparable physicochemical properties and blood plasma profiles with conventional co-loaded liposomes, but the biodistribution proved that sialic acid–octadecylamine modified liposomes accumulated more in tumor. The co-loaded liposomes showed higher tumor growth suppression than the single-drug loaded liposomes, while showing no additional drug toxicity in S180-bearing Kunming mice. The co-loaded liposomes modified with sialic acid–octadecylamine achieved a significantly better antitumor effect, and induced “shedding” of cancerous tissue in the mice. These finding suggested that co-loaded liposomes modified with sialic acid–octadecylamine provided a safe therapeutic strategy with outstanding anticancer activity.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalEuropean Journal of Pharmaceutical Sciences
Volume93
DOIs
Publication statusPublished - 10 Oct 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antitumor
  • Co-loaded liposomes
  • Dexamethasone palmitate
  • Doxorubicin
  • Sialic acid–octadecylamine

Fingerprint

Dive into the research topics of 'Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid–octadecylamine conjugate'. Together they form a unique fingerprint.

Cite this